leadf
logo-loader
ASX:PAR

Paradigm Biopharmaceuticals Ltd

Receive alerts
Market:
ASX
Market Cap:
$561.05 m
Price
2.46 AUD
Change
7.89%
52 weeks high
3.88
52 weeks low
1.08

In brief

Paradigm Biopharmaceuticals Ltd (ASX:PAR) is a late-stage drug development company with the mission to develop and commercialise pentosan polysulphate sodium for the treatment of pain associated with musculoskeletal disorders.

.

Snapshot

Paradigm will be focused on Phase 3 trials of its drug Zilosul® during 2021, COO Jeannie Joughin told Proactive.